Active Ingredient History

  • Now
Sincalide is a synthetically-prepared C-terminal octapeptide of naturally occurring hormone cholecystokinin. Sincalide causes gallbladder contraction and stimulates secretion of pancreatic enzymes, and this property of the drug is used in diagnostic purposes. It is discussed that the drug acts by binding and stimulating the CCK-A receptor which is expressed in the target tissues. FDA approved sincalide under the name KINEVAC.   NCATS

  • SMILES: CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC4=CC=CC=C4)C(N)=O
  • Mol. Mass: 1143.269
  • ALogP: Missing data
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cck | cck-33 | cck-8 | cck c-terminal octapeptide | cck-pz | cholecystokinin | cholecystokinin 33 | cholecystokinin-8 | cholecystokinin c-terminal octapeptide | human cck-33 | human cholecystokinin-33 | kinevac | pancreozymin | pankreozymin | sincalide | sq 19844 | sq-19844 | uropancreozymin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue